SEN病毒合并感染对乙型肝炎患者拉米夫定治疗结局的影响。

Effect of SEN virus coinfection on outcome of lamivudine therapy in patients with hepatitis B.

作者信息

Xu Dong, Tian De-Ying, Zhang Zhen-Gang, Chen Hong-Yun, Song Pei-Hui

机构信息

Department of Infectious Diseases, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Jiefang Street 1095, Wuhan 430030, Hubei Province, China.

出版信息

World J Gastroenterol. 2004 Apr 1;10(7):968-71. doi: 10.3748/wjg.v10.i7.968.

DOI:10.3748/wjg.v10.i7.968

PMID:15052676

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4717114/

Abstract

AIM

Interactions between hepatitis B virus (HBV) and other viral hepatitis infections are well known, whether the newly discovered SEN virus (SENV) has any effect on lamivudine antiHBV activity is unclear. Our aim was to clarify the effect on treatment outcome of coinfection with SEN virus in patients with hepatitis B during lamivudine therapy.

METHODS

Nested polymerase chain reaction (PCR) amplification was used to detect SENV-D and SENV-H strains in serum from 45 patients with chronic hepatitis B treated with lamivudine 100 mg daily for 12 mo. HBV DNA load was detected with fluorescence quantitative PCR (FQ-PCR) and YMDD (tyrosine, methionine, aspartate, aspartate) motif mutation of HBV DNA was investigated with cDNA microarray.

RESULTS

SENV DNA was detected in 5 of 45(11.1%) cases after 12 mo they received lamivudine treatment. SENV-D and SENV-H were 4.4% and 6.7% respectively. HBV DNA failed to respond to lamivudine therapy in 4 of 5 SENV coinfected patients while only 10 of 40 patients became SENV positive and the difference was statistically significant. Response of ALT and HBeAg to lamivudine had no significant difference between coinfection patients and single HBV infection ones.

CONCLUSION

Coinfection with SEN virus in chronic hepatitis B patients may adversely affect the outcome of lamivudine treatment.

摘要

目的

乙型肝炎病毒（HBV）与其他病毒性肝炎感染之间的相互作用已为人熟知，但新发现的SEN病毒（SENV）对拉米夫定抗HBV活性是否有影响尚不清楚。我们的目的是阐明在拉米夫定治疗期间，SEN病毒合并感染对乙型肝炎患者治疗结果的影响。

方法

采用巢式聚合酶链反应（PCR）扩增法检测45例慢性乙型肝炎患者血清中的SENV-D和SENV-H毒株，这些患者每天服用100mg拉米夫定，疗程为12个月。用荧光定量PCR（FQ-PCR）检测HBV DNA载量，并用cDNA微阵列研究HBV DNA的YMDD（酪氨酸、甲硫氨酸、天冬氨酸、天冬氨酸）基序突变。

结果

45例患者接受拉米夫定治疗12个月后，有5例（11.1%）检测到SENV DNA。其中SENV-D和SENV-H分别为4.4%和6.7%。5例SENV合并感染患者中有4例对拉米夫定治疗无反应，而40例患者中只有10例SENV呈阳性，差异有统计学意义。合并感染患者与单纯HBV感染患者的ALT和HBeAg对拉米夫定的反应无显著差异。